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Purpose We report our initial experience with the newly released ultra-
high density (UHD) electroanatomical mapping system (Rhythmia, Boston
Scientific) for arrhythmias. 
Methods All procedures using the multielectrodes catheter (Orion, Boston
Scientific) in our institution, for arrhythmias mapping were analyzed. Proce-
dure and fluoroscopy times were also assessed.
Results 20 patients were included (67,9±13 y) for radiofrequency ablation of
accessory pathway (n=2) / typical flutter (n=5) / atrial fibrillation (AF n=2) / post-
AF ablation left atrial tachycardia (AT n=6) / focal AT (n=2)/ left and right ven-
tricular ectopies (n=3). 63 maps (3,15 maps per patient) were acquired within a
mean mapping time of 18±10min per map, including a mean number of
10024,3±9371 electrograms per map (Figure): RA maps (flutter=12; sinus rhythm
SR=14; coronary sinus CS pacing=4); left atrial maps (during tachycardia=18;
SR=3; CS pacing=4); right ventricular maps (n=4); left ventricular maps (during
tachycardia=3; pacing=1). Acute success was achieved in 19/20 patients. In one
patient, the ablation could not be performed in the absence of clinical ectopies.
Total procedure and fluoroscopy times were respectively 232±78min and 15,9±8
min. No periprocedural complications were noticed.
Conclusion UHD electroanatomical endocardial mapping can be safely
performed in both atria and ventricles and allows fast and accurate mapping.
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Purpose of study to collect history of patients with preexcitation syndrome
(PS)-related adverse event (AE) and evaluate their risk factors. Classicaly
male sex, multiple accessory pathways (AP) and at electrophysiological study
(EPS), refractory period (RP) <250ms and shortest RR interval during atrial
fibrillation (AF) <250ms are signs of risk of AE.
Methods AE occurred in 83 among a population of 970 patients consecu-
tively recruited for a PS (8.5%) (resuscitated sudden death (n=8), or docu-
mented AF conducted with a rapid rate over AP (>300 bpm), cause of syncope
and requiring cardioversion (17) or drug (58). ECG, Holter monitoring and
EPS in control state (CS) and after isoproterenol were performed.
Results Patients with AE were older than remaining patients (40±8.5 vs
33±17) (p 0.0002). Male gender did not differ significantly (71 vs 61%)(p 0.06).
ECG in sinus rhythm was normal or near normal in 20 patients with AE (24%)
more frequently than in patients without AE (9%)(p 0.0001). Intermittent PS
was seen only in patients without AE. At EPS atrioventricular reentrant tachy-
cardia (AVRT) was induced as frequently in patients with AE as in patients
without AE (60% vs 53.5%)(0.22). All other electrophysiological data differ sig-
nificantly (p 0.0001): maximal rate conducted over AP was more rapid in
patients with AE (262±50 bpm vs 183±65 in CS, 302±39 vs 228.5±69 after iso-
proterenol). AP effective refractory period was shorter in patients with AE
(232±34 vs 292±73 in CS, 197±29 vs 232±50ms after isoproterenol); AF was
induced more frequently in patients with AE (72 vs 19.5%). Signs of malig-
nancy at EPS were noted in all but 4 patients (sensitivity 95%).
Conclusion If electrophysiological data evaluated in CS and after iso-
proterenol have high sensitivity (95%) to predict PS-related adverse event, the
detection of PS can be difficult. In 20% of patients who presented with an
adverse event, the diagnosis of PS was not made because ECG in sinus
rhythm was normal. 
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Background Radiofrequency ablation (RFA) is the only curative treatment
for typical atrial flutter (AFL) and allows stopping antiarrhythmic drugs. How-
ever, management of long-term anticoagulant therapy (LT ACT) remains unclear,
especially in lone AFL successfully treated and CHA2DS2VASc score ≥1.
Abstract 0340 – Figure: Ultra high density left atrial macro reentry map
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Aims Assessment of long-term ACT after AFL RFA according to associ-
ated atrial fibrillation (AF) and CHA2DS2VASc score.
Methods From January 2012 to December 2013, patients who underwent
RFA of cavotricuspid isthmus for typical atrial flutter in our centre were ret-
rospectively included.
Results Of 166 patients (137 men, mean age: 66.7±10years), 61 (36.7%)
had a history of AF. The mean CHA2DS2VASc score was 2.49. The patients
were classified according to theoretical indication of LT ACT (patients with a
non rhythmic ACT indication excluded – N=12; 7.2%): group A (LT ACT
unclear) included patients with CHA2DS2VASc score ≥1, successful RF abla-
tion and without AF history (N=74); group B (LT ACT indicated) included
patients with CHA2DS2VASc score ≥1, AF history and/or failed AFL RFA
(N=63); group C (LT ACT not indicated)included patient with
CHA2DS2VASc score=0 (N=17). During a mean follow up of 489±244 days,
45 (60.8), 10 (15.9%) and 11(64.7) patients stopped ACT respectively in
group A, B and C differently according to AF onset (table). There were 8
(4.8%) hemorrhagic and 2 (1.2%) ischemic complications, all in patients with
correct ACT management. The prevalence of AF during follow-up was 38%.
Conclusion After successful AFL RF ablation, ACT was frequently
stopped in the absence of associated AF. However, AF was frequent even
inpatients with no AF history. Ischemic and hemorrhagic complications were
rare. ACT should be regularly evaluated during follow-up especially
according to CHA2DS2VASc score and new onset of AF.
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Purpose Percutaneous left atrial appendage closure (LAAC) is accepted as
a valuable solution for patients (pts) with atrial fibrillation (AF) and high
thromboembolic risk in case of contra-indication to oral anticoagulation
(OAC). Little is known about mid-term results in the real life setting.
Methods We analyzed mid-term results in a dedicated EP team (2 experi-
enced electrophysiologists [AF ablation >200 per yr], 1 echographist, 1 anes-
thesiologist). All indications were discussed before the procedure in a
multidisciplinary approach. 
Procedures were done under general anesthesia in a dedicated EP room
with in-hospital cardiac surgery facilities. All LAAC procedures were per-
formed with Watchman devices (Boston Scientific). 
Results 50 pts were enrolled (male 76%, 77±6 years, paroxysmal AF 44%,
permanent 54%). The CHADS2 VASC average score was 4.6±1,3; ≥4: 76%,
HASBLED score was 3,7±1: ≥4: 64%. All indications were definitive contra-
indications for OAC due to hemorrhagic events (neurological 75%, gastroin-
testinal 13%, ENT 3%, other 4%). The CT-scan ruled out any thrombus before
the procedure for all pts with a perioperative TEE confirmation. Success rate
of implantation was 100% (time of procedure 50±10 min, scopy time 8±3mn).
There were no periprocedure complications.
Postoperative therapy was: antiagregation 31%, double antiagregation
37%, anticoagulation 18%, none 3%. After 2 months, and TEE control, the
initial treatment was switched to: antiagregation 50%, double antiagregation
10%, anticoagulation 10%, none 30%. Mid-term complications were: non
severe pulmonary embolism N=1, recurrent non severe hemorrhagic stroke
N=1, TIA due to carotid stenosis N=1. There were no other adverse events
during 7,4±5 months follow-up.
Conclusion In a single center with large experience in EP, LAAC was per-
formed with a very low rate of complications and excellent mid-term results
regarding recurrences of thromboembolic and hemorrhagic events.
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Introduction The electrophysiological and anatomical properties of the
pulmonary veins (PVs) have been focused on since their crucial role in trig-
gering or generating atrial fibrillation (AF) was first revealed. The presence of
four distinct pulmonary veins (two left PVs and two right PVs) has been
described as the normal variant. 
Aim The purpose of our study was to describe the anatomy of the pulmo-
nary veins in a cohort of patients of our country followed for AF. 
Methods and results Our study is a prospective study which has included
38 patients followed for AF in the cardiology’s department of our Hospital.
All patients underwent a CT scan of PVs in order to characterize their
anatomy. PVs’ size was represented by the largest diameter. 
Our patients had a mean age of 50.5±13 years. The majority of our patients
had paroxysmal AF (65.8%), 4 had persistent AF (10.5%), 9 had prolonged
persistent AF (24%). AF occurred in 63.6% of cases in healthy heart and
36.4% in pathological heart, 13 patients had an anatomical variant which rep-
resent 34.2% of the population. We had 3.9 PVs in average with a minimum
of 3 and a maximum of 5 PVs. The average diameter of different VP was
23.45±9.31mm for the left PVs and 19.75±7mm for the right PVs. 7 patients
(18.4%) had anatomical variants interesting the left PVs with single ostium
forming a core collector left in all cases. 
Concerning the right pulmonary veins, anatomical variations were found in
15.8% of cases, one patient (2.65%) had a single ostium forming a core right
collector and 5 patients (13.15%) had 3 ostia (presence of 1 middle pulmonary
veins on the right). 
Conclusion Cardiac CT is a non invasive procedure which can provide a
detailed evaluation of the anatomy of the pulmonary veins. The presence of
anatomical variations is common in patients with AF. This assessment is
recommended to ensure success of the ablation procedure.
The author hereby declares no conflict of interest
Abstract 0163 – Table: Table Long-term anticoagulation therapy management
A GROUP (N=74) B GROUP (N=63) C GROUP (N=17) 
AF YES (N [%]) NO (N [%]) YES (N [%]) NO (N [%]) YES (N [%]) NO (N [%])
TAC
YES (N [%]) 14 (18.9) 11 (14.9) 29 (46) 20 (31.7) 4 (23.5) 0 (0)
NO (N [%]) 2 (2.7) 43 (58.1) 3 (4.8) 7 (11.1) 6 (35.3) 5 (29.4)
LTFUP (N [%]) 4 (5.4) 4 (6.4) 2 (11.8)
AF: Atrial fibrillation ACT: anticoagulant therapy LTFUP: lost to follow up patient
